丙泊酚与氯胺酮在重症患者快速序贯插管中的比较:一项前瞻性随机对照试验
该研究为研究者发起的随机对照开放标签试验,在两家混合ICU进行,纳入需快速序贯插管的成人(≥18岁),1:1随机分配至氯胺酮或丙泊酚组。主要终点为诱导后10分钟内最低平均动脉压(MAP),采用线性回归模型校正年龄、基线MAP和10分钟内总血管加压药剂量。结果显示氯胺酮组最低MAP为66(55-79)mmHg,丙泊酚组为60(48-72)mmHg,平均差6.0(95%CI -0.0至11.9),p=0.050;心血管崩溃发生率氯胺酮组22%(20/91) vs 丙泊酚组33%(28/84),主要由于2分钟内血管加压药剂量增加。作者认为差异无临床意义且不持续,挑战仅基于低血压风险选择镇静剂的观念,并强调需要更大规模试验确定最佳诱导剂。
要点
- 诱导后10分钟内最低MAP:氯胺酮组66(55-79)mmHg vs 丙泊酚组60(48-72)mmHg,平均差6.0(95%CI -0.0至11.9),p=0.050,差异未达统计学显著且无临床意义。
- 心血管崩溃发生率:氯胺酮组20/91(22%) vs 丙泊酚组28/84(33%),主要由于2分钟内血管加压药剂量增加。
- 第7天死亡率:氯胺酮组33% vs 丙泊酚组23.8%(OR 1.38;95%CI 0.86-2.24);住院死亡率:氯胺酮组60.4% vs 丙泊酚组50.0%(OR 1.21;95%CI 0.92-1.58)。
- 第一小时内平均MAP差异为1.67(95%CI -1.98至5.31),提示两组间MAP差异不持续。
- 作者认为,这些发现挑战了仅基于低血压风险选择镇静剂的观念,并强调需要更大规模试验确定最佳诱导剂。
适用人群与场景
- 两家混合ICU中需要快速序贯插管的成人(≥18岁)重症患者。
处置流程与药物剂量
- 氯胺酮或丙泊酚用于快速序贯插管诱导,1:1随机分配,开放标签;具体剂量、给药途径和频次原文未写明。
研究设计与关键结果
- 研究类型:研究者发起的随机对照开放标签试验,在两家混合ICU进行;2021年10月至2023年10月随机207例,改良意向性分析纳入175例。
- 主要终点:诱导后10分钟内最低MAP,氯胺酮组66(55-79)mmHg vs 丙泊酚组60(48-72)mmHg,平均差6.0(95%CI -0.0至11.9),p=0.050,校正年龄、基线MAP和10分钟内总血管加压药剂量。
- 次要终点:第一小时内平均MAP差异1.67(95%CI -1.98至5.31)。
- 心血管崩溃:氯胺酮组20/91(22%) vs 丙泊酚组28/84(33%),主要由于2分钟内血管加压药剂量增加。
- 第7天死亡率:氯胺酮组33% vs 丙泊酚组23.8%(OR 1.38;95%CI 0.86-2.24);住院死亡率:氯胺酮组60.4% vs 丙泊酚组50.0%(OR 1.21;95%CI 0.92-1.58)。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),开放标签。
- 作者结论:氯胺酮较丙泊酚在最初10分钟内MAP下降幅度较小,但差异无临床意义且不持续;这些发现挑战仅基于低血压风险选择镇静剂的观念,并强调需要更大规模试验确定最佳诱导剂。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,仅基于低血压风险选择镇静剂的观念受到挑战;需要更大规模试验确定最佳诱导剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The optimal hypnotic agent for rapid sequence intubation (RSI) in critically ill patients remains uncertain. We evaluated whether Ketamine is a better alternative than propofol.
METHODS: In this investigator-initiated, randomized, controlled, open-label trial conducted in two mixed ICU, adults (≥ 18 years) requiring RSI were assigned 1:1 to Ketamine or propofol. The primary outcome was the lowest mean arterial pressure (MAP) within the first 10 min after induction, analyzed with a linear regression model adjusted for age, baseline MAP, and total vasopressor dose within 10 min.
RESULTS: From October 2021 to October 2023, 207 patients were randomized and 175 were included in the modified intention-to-treat analysis. The lowest MAP within 10 min was 66 (55-79) mmHg with Ketamine and 60 (48-72) mmHg with propofol (mean difference, 6.0 [95% CI - 0.0 to 11.9]; p = 0.050). The average MAP difference over the first hour was 1.67 (95% CI - 1.98 to 5.31). Cardiovascular collapse occurred in 20/91(22%) Ketamine-treated patients and 28/84 (33%) receiving propofol, mainly due to an increase in the vasopressor dose within 2 min. Day-7 mortality was 33% with Ketamine and 23.8% with propofol (OR 1.38; 95% CI 0.86-2.24). Hospital mortality was 60.4% and 50.0%, respectively (OR 1.21; 95% CI 0.92-1.58).
CONCLUSIONS: Among critically ill patients undergoing RSI, Ketamine resulted in a less pronounced decrease in MAP in the first 10 min compared with propofol, but the difference was not clinically meaningful or sustained. These findings challenge sedative selection based solely on perceived risk of hypotension and highlight the need for larger trials to determine the optimal induction agent.
GOV REGISTRY: NCT05092152-initial release 10.13.2021.
参考来源
- Schmidt RC, Zampieri FG, da Silva Ramos FJ, et al. Propofol versus ketamine in rapid sequence intubation in critically ill patients: a prospective, randomized, controlled trial. Intensive Care Med. 2026. PMID: 41870554. doi:10.1007/s00134-026-08351-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。